At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 20 target
Drug / intervention
Tislelizumab Lenvatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm Study of the Efficacy of Tislelizumab Combined With Lenvatinib in Patients With Stage III-IV Renal Cancer
In Brief
A Phase 2 clinical trial evaluating Tislelizumab Lenvatinib for Advanced Kidney Cancer. Targeting 20 participants across 1 site.
Detailed Summary
This is a phase II study to determine the efficacy and safety of Tislelizumab when given in combination with Lenvatinib as treatment for patients with the advanced kidney cancer . Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Kidney Cancer
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
2023202420252026
Enrollment StartJul 2022
First PostedAug 2022
Primary CompletionDec 2023
Study CompletionDec 2025
TodayJul 2026
First PostedAug 3, 2022
Enrollment StartJul 1, 2022
Primary CompletionDec 31, 2023
Study CompletionDec 31, 2025
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 3.9 years ago
Interventions
Tislelizumab Lenvatinibdrug
Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects